Avenzo Therapeutics, Inc. has announced plans to present preliminary Phase 1 results from ORION-1, its ongoing Phase 1/2 clinical study of the investigational selective cyclin-dependent kinase 4 inhibitor AVZO-023, at the 2026 San Antonio Breast Cancer Symposium. Announced on October 30, 2026, the presentation will focus on safety, tolerability and preliminary antitumour activity when AVZO-023 is combined with fulvestrant in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
The presentation is scheduled for December 9, 2026, during the symposium taking place from December 8 to 11 in San Antonio, Texas. It represents an important clinical development milestone for Avenzo Therapeutics because the company is seeking to demonstrate whether selectively inhibiting CDK4 can deliver meaningful antitumour activity while potentially avoiding some toxicities associated with inhibiting both CDK4 and CDK6.
However, Avenzo Therapeutics has not disclosed numerical efficacy or safety results in its October announcement. The scheduled presentation does not establish that AVZO-023 has demonstrated clinical benefit, superior tolerability or an advantage over approved treatments. Those questions will depend on the actual Phase 1 findings and subsequent clinical investigations.
Why is the first ORION-1 clinical presentation important for Avenzo Therapeutics’ breast cancer strategy?
The ORION-1 programme represents Avenzo Therapeutics’ effort to advance a selective CDK4 inhibitor within an increasingly competitive treatment landscape. Its initial clinical investigation is designed to establish how AVZO-023 behaves in patients, including tolerability, drug exposure and evidence of preliminary antitumour activity. These findings will help determine which doses and treatment combinations are suitable for further development.
The Phase 1/2 study, registered as NCT06998407, is an open-label, first-in-human investigation evaluating AVZO-023 alone and in combinations with endocrine therapy and the company’s investigational CDK2 inhibitor, AVZO-021. Its Phase 1 component focuses on safety, pharmacokinetics, pharmacodynamics and dose selection. The subsequent Phase 2 component is intended to assess antitumour activity and confirm the recommended treatment regimen.
The December presentation will specifically examine AVZO-023 in combination with fulvestrant. This is a narrower evidence package than the complete ORION-1 development programme, which also includes other treatment approaches. Results from the fulvestrant combination should therefore not be interpreted as establishing the performance of AVZO-023 monotherapy or the proposed three-drug regimen.
The presentation is identified as abstract 2618 and poster P1-4-13. It is scheduled for December 9 between 12:30 p.m. and 2 p.m. Central Time at the Henry B. González Convention Center. The forthcoming dataset will provide the first opportunity to evaluate whether the company’s pharmacological differentiation hypothesis is supported by human clinical observations.
How does selective CDK4 inhibition differ from established CDK4/6 treatment in metastatic breast cancer?
Cyclin-dependent kinases regulate progression through different stages of the cell cycle. CDK4 and CDK6 work with cyclin D proteins to influence the transition from the G1 phase towards DNA synthesis. Abnormal activation of this pathway can contribute to uncontrolled proliferation in hormone receptor-positive breast cancer.
Established CDK4/6 inhibitors have substantially changed treatment for hormone receptor-positive, HER2-negative advanced breast cancer. Medicines such as palbociclib, ribociclib and abemaciclib have demonstrated clinical benefit in appropriately selected patients when used with endocrine therapy. Their mechanisms involve inhibition of both CDK4 and CDK6, although the individual drugs differ in selectivity, pharmacology and adverse-event profiles.
Avenzo Therapeutics is investigating whether more selective CDK4 inhibition can preserve the intended antitumour effect while reducing interference with CDK6-related physiological functions. CDK6 is involved in haematopoietic cell development, making it relevant to certain blood-related toxicities associated with dual CDK4/6 inhibition. However, the relationship between kinase selectivity and clinical adverse events is more complicated than a single molecular distinction.
AVZO-023 is designed to inhibit CDK4 and cyclin D-mediated signalling while substantially sparing CDK6. In principle, this may reduce some haematological effects and allow clinically useful exposure to be maintained. Nevertheless, improved tolerability remains a hypothesis until supported by comparative clinical evidence.
The first Phase 1 results will therefore be relevant for evaluating treatment-associated neutropenia and other blood-count abnormalities. Investigators will also need to assess non-haematological adverse events and determine whether the compound can achieve exposure levels compatible with sustained CDK4 inhibition.
Why is fulvestrant an important combination partner for AVZO-023 in advanced breast cancer?
Fulvestrant is an endocrine therapy that acts through the oestrogen receptor pathway, which drives growth in many hormone receptor-positive breast cancers. It binds to the receptor and promotes its degradation, reducing signalling associated with tumour proliferation. This makes it a clinically relevant partner for medicines targeting complementary cell-cycle mechanisms.
Combining endocrine therapy with CDK pathway inhibition is an established treatment principle in breast cancer. The endocrine component addresses hormone-dependent signalling, while CDK inhibition seeks to interrupt downstream processes involved in cell division. Avenzo Therapeutics is investigating whether selective CDK4 inhibition can support this complementary approach.
The ORION-1 study evaluates AVZO-023 with fulvestrant in patients with advanced or metastatic disease. The trial’s broader design also includes evaluation with letrozole and other investigational combinations. However, the December presentation concerns preliminary results from the AVZO-023 and fulvestrant regimen rather than the entire programme.
Clinical interpretation will depend on the treatment histories of enrolled patients. Individuals who have previously received CDK4/6 inhibitors may differ substantially from patients who are less heavily treated, particularly because resistance mechanisms can influence subsequent responses. The October announcement does not specify the number of participants represented in the forthcoming analysis or provide their complete previous treatment characteristics.
Consequently, any reported tumour response will need to be interpreted alongside patient selection, prior therapy exposure and dose level. A favourable response in a small Phase 1 cohort would support further investigation but would not establish superiority over approved endocrine-based treatment combinations.
Could sparing CDK6 reduce haematological toxicity without compromising antitumour activity?
Haematological toxicity is an important consideration with some established CDK4/6 inhibitors. Neutropenia, characterised by reduced neutrophil counts, can require dose interruptions or reductions and additional monitoring. Its frequency and severity vary between medicines, reflecting differences in their pharmacological properties and clinical dosing.
Avenzo Therapeutics’ development hypothesis is that selective CDK4 inhibition may reduce certain blood-related adverse events while maintaining inhibition of a pathway important to tumour proliferation. If supported clinically, this could potentially allow greater dosing flexibility or make combination treatment more manageable. However, CDK6 sparing is not a guarantee of an improved safety profile.
The Phase 1 evaluation will need to determine whether AVZO-023 produces dose-related haematological abnormalities and whether these effects limit treatment exposure. Researchers must also examine gastrointestinal symptoms, fatigue, liver function abnormalities and other adverse events relevant to long-term oral oncology treatment. A lack of one specific toxicity would not establish broad tolerability if other clinically important complications emerge.
Drug exposure is another important variable. Selective molecular inhibition must occur at concentrations that can be achieved safely in patients. If the dose needed for meaningful tumour suppression causes adverse effects through other mechanisms, the theoretical advantage of CDK6 sparing could become less clinically significant.
The forthcoming results may provide an initial indication of the compound’s therapeutic window. Nevertheless, a definitive claim of reduced toxicity would require appropriate comparison with established treatments and sufficient patient exposure to assess uncommon or delayed events.
How does AVZO-021 fit into Avenzo Therapeutics’ strategy to address CDK4/6 inhibitor resistance?
Avenzo Therapeutics is developing AVZO-021 as a selective oral inhibitor of CDK2, another cell-cycle kinase involved in tumour proliferation. CDK2 activity is associated with the cyclin E pathway, which can contribute to resistance when cancer cells reduce their dependence on CDK4/6 signalling. This creates a biological rationale for investigating combinations that target both pathways.
The company has already advanced AVZO-021 through Phase 1 evaluation as monotherapy and in combination with fulvestrant. According to its latest disclosure, enrolment in that Phase 1 component has been completed. However, the October announcement does not provide numerical efficacy or safety findings from the completed enrolment phase.
In May 2026, Avenzo Therapeutics announced first-patient dosing in an ORION-1 combination cohort evaluating AVZO-023, AVZO-021 and fulvestrant. The triplet strategy is intended to inhibit CDK4-driven cell proliferation while addressing a potential CDK2-mediated resistance mechanism. Its rationale is particularly relevant to patients whose tumours have progressed following previous endocrine and CDK4/6-directed treatment.
Combining kinase inhibitors may increase antitumour pathway coverage, but it can also introduce additional safety challenges. Researchers must determine whether simultaneous inhibition produces acceptable tolerability and whether each component contributes meaningful activity. Drug interactions and overlapping toxicities could influence the doses suitable for combination treatment.
The triplet’s clinical value cannot be established from the upcoming AVZO-023 and fulvestrant presentation alone. That dataset may help inform dose selection and the rationale for further combinations, but dedicated results will be required to evaluate whether the addition of AVZO-021 improves clinical outcomes.
Why will previous CDK4/6 treatment and tumour resistance mechanisms influence the interpretation of ORION-1?
Hormone receptor-positive, HER2-negative metastatic breast cancer is biologically diverse, and patients may develop resistance through several mechanisms. These can include changes in oestrogen receptor signalling, cell-cycle regulation and other molecular pathways. The effectiveness of a new CDK inhibitor may therefore depend on the resistance characteristics of the tumour.
One important consideration is the retinoblastoma protein pathway, which is involved in controlling cell-cycle progression downstream of CDK activity. Tumours with functional loss of RB1 may be less responsive to treatments relying on this regulatory mechanism. The ORION-1 eligibility criteria exclude patients with confirmed RB1 loss-of-function mutation or deletion, reflecting the importance of pathway biology to the programme.
The study also incorporates clinical eligibility requirements concerning prior treatments, organ function and general patient condition. Such criteria help define a population suitable for early investigation but may limit how directly the results can be generalised to broader metastatic breast cancer practice.
When the first data are presented, the distribution of previous endocrine therapy and CDK4/6 inhibitor exposure will be important. Responses among patients who have progressed on established therapy may have different implications from those observed in less heavily treated individuals. Researchers will also need to distinguish objective tumour responses from stable disease and other preliminary measures of activity.
The maturity of follow-up will influence interpretation of any efficacy signal. A response observed during initial treatment may support continued study, but durability and progression-free survival require longer observation. Phase 1 findings are unlikely to establish the full clinical role of AVZO-023 without larger, appropriately designed investigations.
What does Avenzo Therapeutics’ licensing relationship with Allorion Therapeutics mean for its oncology portfolio?
Avenzo Therapeutics holds exclusive global development, manufacturing and commercialisation rights to AVZO-023 outside Greater China through an agreement with Allorion Therapeutics. It has a corresponding territorial rights arrangement for AVZO-021. These agreements provide Avenzo with control over the development programmes in its licensed markets while preserving the territorial exclusions established by the transactions.
The relationship supports a strategy built around selective cell-cycle inhibitors and rational treatment combinations. Avenzo is developing the assets within its own clinical programmes rather than marketing approved versions of the medicines. Their commercial value will depend on future clinical results, regulatory decisions and the terms governing the licensing arrangements.
The company’s wider oncology pipeline includes bispecific antibody-drug conjugates. AVZO-1418, an investigational EGFR/HER3-directed antibody-drug conjugate, is being evaluated in the Phase 1/2 AVENTINE-1 study. AVZO-103, targeting Nectin-4 and TROP2, is being studied through the Phase 1/2 BEACON-1 programme.
These additional assets diversify Avenzo’s development activities beyond cell-cycle inhibition. However, their presence does not independently strengthen the evidence supporting AVZO-023 or reduce the clinical uncertainty associated with ORION-1. Each programme must generate its own safety and efficacy evidence.
Avenzo Therapeutics is privately held, and the October announcement does not disclose a new financing transaction or a valuation associated with the forthcoming presentation. The December results may influence future partnering and investment discussions, but any commercial conclusions will depend on the actual data rather than the scheduled conference appearance.
What will investigators and potential partners examine in the December AVZO-023 Phase 1 dataset?
The most important information will concern safety, exposure and the initial relationship between dose and antitumour activity. Investigators will examine adverse-event rates, serious treatment-related events, dose reductions and discontinuations. Information about neutropenia will be particularly relevant because avoiding CDK6-associated haematological toxicity is part of the compound’s development rationale.
Pharmacokinetic and pharmacodynamic findings could help establish whether AVZO-023 reaches concentrations consistent with effective CDK4 inhibition. The recommended dose for subsequent investigation will depend on the overall benefit-risk profile rather than the highest dose tolerated during escalation. Researchers may also examine molecular characteristics associated with preliminary activity.
Any efficacy results will require careful interpretation. Objective response rates, disease control and duration of response are useful early measures, but their meaning depends on sample size and the characteristics of treated patients. A small uncontrolled cohort cannot establish that the treatment is superior to existing CDK4/6 inhibitor combinations.
The December poster may also clarify the future direction of the broader ORION-1 programme. Results could support dose expansion, refinement of patient selection or further development of the AVZO-023 and AVZO-021 triplet. However, the October announcement does not confirm the outcome of any of these decisions.
For Avenzo Therapeutics, the first Phase 1 presentation is an opportunity to move its selective CDK4 strategy from molecular rationale towards clinical evidence. The company has identified a plausible path to differentiation through CDK6 sparing and combination treatment, but neither advantage has yet been established in patients. The determining evidence will be whether ORION-1 demonstrates meaningful antitumour activity at doses that offer an acceptable and potentially distinctive tolerability profile.
